Physician profile
David Lim
NPI 1295362069
$1,120.76
in general payments reported to CMS, 2019-2025
13 companies · $966 in 2025
The $966 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $155 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $313.56 | 2025 | Otezla, Tavneos |
| Mallinckrodt Hospital Products INC. | $127.64 | 2025 | Acthar |
| Ucb, INC. | $109.44 | 2025 | Bimzelx |
| Radius Health, INC. | $106.93 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Ani Pharmaceuticals, INC. | $70.85 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $70.27 | 2025 | |
| Glaxosmithkline, LLC. | $65.64 | 2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $55.54 | 2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $36.26 | 2025 | Orencia |
| Janssen Biotech, INC. | $26.72 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $25.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.